Carlo Incerti, MD
A medical doctor by training, Carlo Incerti brings over three decades of experience in the biopharmaceutical industry. He most recently held the position of Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs at Sanofi Genzyme.
Prior to its acquisition by Sanofi in 2011, Carlo held a number of positions of increasing scope and responsibility at Genzyme Corporation, the company who pioneered the development of therapeutics for rare diseases , working first at the European Headquarters in the Netherlands (1993-2010) before being appointed Senior Vice President of Global Market Access (2010-2011) at the corporate headquarters in Boston, MA.
Before his time at Sanofi and Genzyme, Carlo was a founding shareholder, Board member and Chief Executive officer at Biofil S.r.l., a start-up active in the development, manufacturing and commercialization of systems for leukocyte depletion of blood and derivatives, which was acquired by Fresenius Kabi of Germany in 1993.
Prior to join industry Carlo was an Associate Professor of Endocrinology at the University of Modena, with a main research focus on thyroid diseases and sex hormones.
Dr Incerti is also Chairman of the Board at Molmed, S.p.a., a public Italian company active in cell & gene therapy, an Independent Member of the Board of Gotham Therapeutcs, a leading company in the field of epitrascriptomics, a Member of the Board of EuropaBio and a Founding Member and on the Consortium Assembly of IRDiRC, the International Rare Diseases Research Consortium.